The Week in Review: September 29, 2017 – October 6, 2017
Obesity and liver cancer, global rise in primary liver cancer, AASLD-IDSA HCV Guidelines updated, Viekira Pak (Holkira Pak) safe in compensated cirrhotics, First Nations gain access to BC PharmaCare, new studies on HBV ……..
The Week in Review: September 22, 2017 – September 29, 2017
Merck discontinues HCV development program, Canadian Federation of Nurses Unions responds to federal pharmacare plans, coffee reduces overall mortality risk in coinfected persons, Mexican-Americans have higher liver cancer risk than Mexicans, Call for input for Vemlidy, Per-SVR (pronounced “Persevere!”) Study is Recruiting Participants, HepCBC on the front lines and more ……..
The Week in Review: September 15, 2017 – September 22, 2017
Epclusa approved for HIV-HCV coinfection in Canada, generic sofosbuvir approved in Malaysia, unrestricted access to Epclusa and Harvoni in Switzerland, new study on financial burden of liver disease, predictors of fibrosis progression in HBV……..
The Week in Review: September 8, 2017 – September 15, 2017
Rosemary Plummer steps down as President of HepCBC; rest of the Board re-elected at AGM; Women and HCV; How Liver Cancer Develops; Global Burden of Disease, Johnson & Johnson pulls plug on Medivir-Achillion hep C cocktail to focus on hep B……..
The Week in Review: September 1, 2017 – September 8, 2017
Mystery illness solved, DAAs and kidney disease, drug paraphernalia and transmission, fibrosis progression in men and the last word on DAAs and HCC?